Novartis Simulect, Neoral, Cellcept Transplant Rejection Trial Underway
Executive Summary
Novartis is conducting a renal transplant rejection trial with a regimen that includes its newly approved IL-2 receptor antagonist Simulect, its cyclosporine microemulsion Neoral, and Roche's Cellcept plus steroids.